Suppuration: Clinical Trials

10 active not recruiting. 10 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	10	Active not recruiting 10
Phase 2	1	Active not recruiting 1

Follow Suppuration: new trials by email Literature Review of Suppuration trials Research Report on Suppuration

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa BFB759, Placebo for BFB759 - Hidradenitis Suppurativa (HS)	Phase 2 / Phase 3	Active not recruiting	Bluefin Biomedicine, Inc.	210	2025-11-03	2026-10-14
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) Ruxolitinib Cream, Vehicle Cream - Hidradenitis Suppurativa	Phase 3	Active not recruiting	Incyte Corporation	580	2025-06-23	2026-07-28
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) Ruxolitinib Cream, Vehicle Cream - Hidradenitis Suppurativa	Phase 3	Active not recruiting	Incyte Corporation	573	2025-06-12	2026-07-08
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa Bimekizumab - Hidradenitis Suppurativa	Phase 3	Active not recruiting	UCB Biopharma SRL	43	2025-04-07	2026-09-25
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1 - Hidradenitis Suppurativa	Phase 3	Active not recruiting	Novartis Pharmaceuticals	565	2025-03-20	2026-10-15
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1 - Hidradenitis Suppurativa	Phase 3	Active not recruiting	Novartis Pharmaceuticals	588	2025-01-31	2026-10-15
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) Sonelokimab - Hidradenitis Suppurativa	Phase 3	Active not recruiting	MoonLake Immunotherapeutics AG	35	2024-12-30	2026-05-06
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Lutikizumab, Placebo - Hidradenitis Suppurativa	Phase 3	Active not recruiting	AbbVie	1400	2024-06-27	2026-09-02
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa Povorcitinib - Hidradenitis Suppurativa (HS)	Phase 3	Active not recruiting	Incyte Corporation	617	2024-01-30	2026-08-25
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy Upadacitinib, Placebo - Hidradenitis Suppurativa	Phase 3	Active not recruiting	AbbVie	1328	2023-06-21	2026-08-20

Narrower conditions

Hidradenitis Suppurativa (10)  ·  Hidradenitis (4)  ·  Skin Diseases (3)  ·  Dermatitis (2)  ·  Skin Diseases, Bacterial (1)  ·  Sweat Gland Diseases (1)

Broader conditions

Bacterial Infections (10)  ·  Bacterial Infections and Mycoses (10)  ·  Infections (10)  ·  Skin Diseases, Infectious (10)  ·  Skin and Connective Tissue Diseases (10)  ·  Skin Diseases, Bacterial (9)  ·  Sweat Gland Diseases (9)  ·  Skin Diseases (7)  ·  Hidradenitis (6)  ·  Inflammation (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

remibrutinib (2)  ·  bimekizumab (1)  ·  lutikizumab (1)  ·  sonelokimab (1)  ·  upadacitinib (1)

Sponsors

Incyte Corporation (3)  ·  AbbVie (2)  ·  Novartis Pharmaceuticals (2)  ·  Bluefin Biomedicine, Inc. (1)  ·  MoonLake Immunotherapeutics AG (1)  ·  UCB Biopharma SRL (1)

Countries

United States (10)  ·  Germany (9)  ·  Canada (8)  ·  Poland (8)  ·  Spain (8)  ·  Bulgaria (7)  ·  France (6)  ·  Belgium (5)  ·  Czechia (5)  ·  Greece (5)  ·  Italy (5)  ·  Argentina (4)  ·  Australia (4)  ·  Austria (4)  ·  Colombia (4)

NIH funding

2023 (3)